Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | BRS3 | P32247 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694526 | 0.85 | HPGD (0.31) | HPGD | |
| SCHEMBL7255595 | 0.81 | HPGD (0.32) | HPGD | |
| SCHEMBL6697422 | 0.73 | HPGD (0.31) | HPGD | |
| SCHEMBL6701653 | 0.71 | REN (0.35) | HPGDLMNAPOLBHTT | |
| SCHEMBL6701979 | 0.65 | MAPK1 (0.44) | MEN1ALDH1A1KMT2AMAPTNPSR1 | |
| SCHEMBL5465845 | 0.64 | MAPT (0.60) | MEN1ALDH1A1KMT2AMAPTLMNA | |
| SCHEMBL6695836 | 0.61 | CYP2C9 (0.37) | MEN1ALDH1A1KMT2AMAPTNPSR1 | |
| SCHEMBL5470380 | 0.61 | BRPF1 (0.41) | MEN1ALDH1A1KMT2AMAPTLMNA | |
| SCHEMBL5473498 | 0.59 | HSD17B3 (0.42) | MEN1ALDH1A1KMT2AMAPTLMNA | |
| SCHEMBL5193417 | 0.57 | GSK3A (0.51) | HPGDMEN1ALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009972-A1 | Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase | BRISTOL-MYERS COMPANY | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009972-A1 | Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase | MT-ATP6, MT-CO1, ATP5ME | HPGD 947/4885MEN1 2698/4885ALDH1A1 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.